Preview Mode Links will not work in preview mode

JACC Journals podcasts deliver expert insights and key takeaways from the latest cardiovascular science. Hosted by Editor-in-Chief Harlan M. Krumholz, MD, SM, JACC This Week offers engaging summaries and commentary from each weekly issue, complemented by a growing library of deep-dive interviews, global perspectives, and author conversations that highlight the research and innovation shaping cardiovascular medicine worldwide.

  1. All Episodes
  2. Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs. Second-Generation DES: TARGET-IV NA Trial

Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs. Second-Generation DES: TARGET-IV NA Trial

Oct 30, 2024

Author Robert W. Yeh, MD, FACC, and JACC Associate Editor Celina M. Yong, MD, FACC, discuss the results of the TARGET-IV NA trial. In the trial, 1720 patients with stable or acute coronary syndromes were randomized to undergo PCI with a BP-SES or any commonly used 2nd generation DES. At 12 months, BP-SES was non-inferior to control DES for the primary endpoint of Target Lesion Failure (cardiac death, target vessel-related myocardial infarction (MI), or ischemia-driven target lesion revascularization) which occurred in 3.4% of the BP-SES arm versus 3.3% in the control arm; p-value for non-inferiority. Secondary endpoints were also similar between groups.